Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.
Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.